Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Halfdan Sorbye; Eric Baudin; Ivan Borbath; Martyn Caplin; Jie Chen; Jaroslaw B. Cwikla; Andrea Frilling; Ashley Grossman; Gregory Kaltsas; Aldo Scarpa; Staffan Welin; Rocio Garcia-Carbonero

doi:10.1159/000493318

Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Halfdan Sorbye, Eric Baudin, Ivan Borbath, Martyn Caplin, Jie Chen, Jaroslaw B. Cwikla, Andrea Frilling, Ashley Grossman, Gregory Kaltsas, Aldo Scarpa, Staffan Welin, Rocio Garcia-Carbonero

Research output: Contribution to journal › Article › peer-review

67 Citations (Scopus)

Abstract

Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are classified based on morphology and graded based on their proliferation rate as either well-differentiated low-grade (G1 to G2) neuroendocrine tumors (NET) or poorly differentiated high-grade (G3) neuroendocrine carcinomas (NEC). Recently, a new subgroup of well-differentiated high-grade pancreatic tumors (NET G3) has been defined. The GEP NEN G3 group consisting of both NEC and NET G3 has recently been shown to be a quite heterogeneous patient group concerning prognosis and treatment benefit, depending on factors such as the primary tumor site, differentiation, proliferation rate, and molecular alterations. In this review we discuss the existing data on diagnostics, treatment, and biomarkers in this patient group, the unmet needs, and the future perspectives.

Original language	English
Pages (from-to)	54-62
Number of pages	9
Journal	Neuroendocrinology
Volume	108
Issue number	1
DOIs	https://doi.org/10.1159/000493318
Publication status	Published - 1 Jan 2019

Keywords

Neuroendocrine carcinoma
Neuroendocrine neoplasm
Neuroendocrine tumor

Access to Document

10.1159/000493318

Cite this

@article{f186c3accd884aa193ea9ac4b81a1f6f,

title = "Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)",

abstract = "Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are classified based on morphology and graded based on their proliferation rate as either well-differentiated low-grade (G1 to G2) neuroendocrine tumors (NET) or poorly differentiated high-grade (G3) neuroendocrine carcinomas (NEC). Recently, a new subgroup of well-differentiated high-grade pancreatic tumors (NET G3) has been defined. The GEP NEN G3 group consisting of both NEC and NET G3 has recently been shown to be a quite heterogeneous patient group concerning prognosis and treatment benefit, depending on factors such as the primary tumor site, differentiation, proliferation rate, and molecular alterations. In this review we discuss the existing data on diagnostics, treatment, and biomarkers in this patient group, the unmet needs, and the future perspectives.",

keywords = "Neuroendocrine carcinoma, Neuroendocrine neoplasm, Neuroendocrine tumor",

author = "Halfdan Sorbye and Eric Baudin and Ivan Borbath and Martyn Caplin and Jie Chen and Cwikla, {Jaroslaw B.} and Andrea Frilling and Ashley Grossman and Gregory Kaltsas and Aldo Scarpa and Staffan Welin and Rocio Garcia-Carbonero",

year = "2019",

month = jan,

day = "1",

doi = "10.1159/000493318",

language = "English",

volume = "108",

pages = "54--62",

journal = "Neuroendocrinology",

issn = "0028-3835",

number = "1",

}

TY - JOUR

T1 - Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

AU - Sorbye, Halfdan

AU - Baudin, Eric

AU - Borbath, Ivan

AU - Caplin, Martyn

AU - Chen, Jie

AU - Cwikla, Jaroslaw B.

AU - Frilling, Andrea

AU - Grossman, Ashley

AU - Kaltsas, Gregory

AU - Scarpa, Aldo

AU - Welin, Staffan

AU - Garcia-Carbonero, Rocio

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are classified based on morphology and graded based on their proliferation rate as either well-differentiated low-grade (G1 to G2) neuroendocrine tumors (NET) or poorly differentiated high-grade (G3) neuroendocrine carcinomas (NEC). Recently, a new subgroup of well-differentiated high-grade pancreatic tumors (NET G3) has been defined. The GEP NEN G3 group consisting of both NEC and NET G3 has recently been shown to be a quite heterogeneous patient group concerning prognosis and treatment benefit, depending on factors such as the primary tumor site, differentiation, proliferation rate, and molecular alterations. In this review we discuss the existing data on diagnostics, treatment, and biomarkers in this patient group, the unmet needs, and the future perspectives.

AB - Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are classified based on morphology and graded based on their proliferation rate as either well-differentiated low-grade (G1 to G2) neuroendocrine tumors (NET) or poorly differentiated high-grade (G3) neuroendocrine carcinomas (NEC). Recently, a new subgroup of well-differentiated high-grade pancreatic tumors (NET G3) has been defined. The GEP NEN G3 group consisting of both NEC and NET G3 has recently been shown to be a quite heterogeneous patient group concerning prognosis and treatment benefit, depending on factors such as the primary tumor site, differentiation, proliferation rate, and molecular alterations. In this review we discuss the existing data on diagnostics, treatment, and biomarkers in this patient group, the unmet needs, and the future perspectives.

KW - Neuroendocrine carcinoma

KW - Neuroendocrine neoplasm

KW - Neuroendocrine tumor

UR - http://www.scopus.com/inward/record.url?scp=85060177166&partnerID=8YFLogxK

U2 - 10.1159/000493318

DO - 10.1159/000493318

M3 - Article

C2 - 30153658

AN - SCOPUS:85060177166

SN - 0028-3835

VL - 108

SP - 54

EP - 62

JO - Neuroendocrinology

JF - Neuroendocrinology

IS - 1

ER -

Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Abstract

Keywords

Access to Document

Other files and links

Cite this